Voskaridou, Ersi <br/><br/>
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.  [electronic resource] 

 -  Blood advances  11 2018 
 - 2837-2847 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2473-9537 
<br/><br/><label>Standard No.: </label>10.1182/bloodadvances.2018023085  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Bone Density<br/>Bone Density Conservation Agents--adverse effects<br/>Bone Remodeling<br/>Collagen Type I--metabolism<br/>Denosumab--adverse effects<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Headache--etiology<br/>Humans<br/>Male<br/>Middle Aged<br/>Osteoporosis--drug therapy<br/>Osteoprotegerin--metabolism<br/>Peptides--metabolism<br/>Placebo Effect<br/>RANK Ligand--metabolism<br/>Thalassemia--complications<br/>Treatment Outcome